# Peptide Label Key

> How PepFlow explains peptide tier grades, evidence percentages, safety labels, FDA status chips, and injectable 503A compounding labels.

Canonical: https://pepflow.app/peptide-label-legend/

Use this page to read PepFlow's tier grades, evidence percentages, safety labels, FDA status chips, and injectable 503A compounding labels consistently.

Jump To

## Tiers

Tier colors preserve the existing PepFlow grade palette. Tier is a usefulness grade, not just an evidence score.

| Label | Signal | Meaning | Rationale |
| --- | --- | --- | --- |
| S | Top tier | Highest practical usefulness with strong, clinically established evidence. | Reserved for entries where the claim is both useful and unusually well supported. |
| A | High tier | Strong usefulness with substantial human evidence. | Used when a peptide has a clear practical role and the supporting evidence is broad enough for high confidence. |
| B | Useful tier | Useful, with moderate or promising human evidence and clear caveats. | A good signal, but still limited by route, formulation, outcome size, or source maturity. |
| C | Mixed tier | Mixed or emerging evidence; useful context but not settled. | The peptide may be worth tracking, but the page should not read like the benefit is established. |
| D | Early tier | Preliminary or indirect evidence with meaningful limitations. | Usually driven by small studies, adjacent evidence, route mismatch, or mostly mechanistic support. |
| E | Weak tier | Mostly preclinical, weak, or low-usefulness evidence. | The claim may be biologically plausible, but it is not ready for practical confidence. |
| F | Insufficient tier | Insufficient reviewed evidence for practical usefulness. | Used when PepFlow should avoid implying a usable effect from the reviewed source base. |
| WIP | Not reviewed | The record is present, but its evidence, safety, or regulatory review is not complete. | Neutral prevents missing review work from looking like either a low grade or a safety signal. |

## Evidence percentages

Evidence percentages summarize confidence in the reviewed claim. Each label uses its own display band.

| Label | Percent | Meaning | Rationale |
| --- | --- | --- | --- |
| Strong | 80-100% | Consistent human data, approved-label context, or very strong clinical support. | This is the highest evidence-confidence bucket and should stay route-specific. |
| Moderate | 65-79% | Some direct human evidence plus coherent preclinical or mechanistic support. | Enough support to discuss confidently, while keeping limitations visible. |
| Emerging | 50-64% | Early or limited human data exists, usually narrow, indirect, uncontrolled, or not yet replicated. | Keeps the chip in the same confidence-language family while the detail text explains the human-data limits. |
| Preliminary | 35-49% | Early signals, active trials, indirect human context, or plausible translational support. | Marks a lower-confidence stage without mixing source type into the chip label. |
| Limited | 20-34% | Mostly animal, cell, formulation, or mechanism data, with little direct human outcome support. | Keeps biological plausibility visible without making the chip compete with the rest of the scale. |
| Insufficient | 1-19% | Not enough reviewed evidence for a confident claim. | Prevents weak or unsupported claims from looking merely early-stage. |
| Not Reviewed | 0% | No evidence assessment has been added yet. | Neutral means missing review, not proof that the peptide does or does not work. |

## Safety labels

Safety labels describe the caution context. A peptide can have strong evidence and still need strict safety or route limits.

| Label | Signal | Meaning | Rationale |
| --- | --- | --- | --- |
| Well-Studied | Best-characterized | Substantial human safety data exists for the same molecule, route, and typical use. This does not mean risk-free. | Use only when the relevant human safety profile is mature enough to be well characterized. |
| Moderate Data | Some safety context | Relevant human safety data exists, but it is smaller, shorter, narrower, or less complete than a well-studied profile. | Use when the evidence supports practical safety context without supporting a mature or broadly established profile. |
| Limited Data | Higher uncertainty | Relevant human safety data is sparse, indirect, route-mismatched, or too early to characterize the typical use confidently. | Use for evidence uncertainty. Lack of approval, a sports prohibition, or one contaminated batch does not determine this label by itself. |
| High Caution | High caution | Serious human harm or an explicit authoritative avoid or stop warning is relevant to the same molecule, route, and typical use. | Use only when the concern is attributable to the substance or use—not merely lack of approval, limited data, sports prohibition, or one contaminated product batch. |
| Not Reviewed | Not reviewed | The route- and use-specific safety classification has not been completed. | This is a review state, not a judgment that the substance is safe or dangerous. |

## FDA / regulatory

Regulatory labels are reusable status buckets for FDA approval, compounding, cosmetics, sport rules, and future regulatory systems. The page detail explains the specific entity and route.

| Label | Signal | Meaning | Rationale |
| --- | --- | --- | --- |
| Approved | Authorized | An approval or authorization exists for the reviewed product, route, or claim context. | The chip stays reusable; the page detail should identify the regulator, product, indication, route, and label. |
| Not Approved | No approval identified | No approval or authorization is identified for the reviewed product, route, or claim context. | This is red because readers often confuse availability, research use, or compounding with approval. |
| Non-Drug | Claim-specific context | The reviewed context is cosmetic, non-drug, or otherwise separate from therapeutic drug approval. | Keeps cosmetic or non-drug availability separate from an approved medical claim. |
| Under Review | Review in progress | A regulator, compounding process, or review body is still evaluating the status. | Under review does not mean approved, safe, prohibited, or clinically established. |
| Flagged | Restriction or risk flag | A regulatory safety-risk flag, restriction, exclusion, or sport/anti-doping prohibition applies. | Red is reserved for reviewed regulatory constraints that need visible caution. |
| Not Listed | No listing found | The substance, route, or product was not listed in the reviewed regulatory material. | Not listed is not an approval or safety statement. |
| Not Reviewed | Not reviewed | The regulatory status has not been reviewed for that page yet. | Neutral keeps unfinished content separate from a reviewed regulatory conclusion. |

## Injectable 503A

Injectable 503A uses the same simplified regulatory states, but it stays separate because injectable compounding has different sterility, impurity, and route-specific concerns.

| Label | Signal | Meaning | Rationale |
| --- | --- | --- | --- |
| Under Review | Review in progress | The injectable route appears in a 503A evaluation bucket, but the review is not complete. | This is a process state, not approval. |
| Flagged | Safety-risk flag | The injectable compounding route has been tied to FDA safety-risk concerns. | Injectable exposure raises sterility, impurities, aggregation, immunogenicity, and dose-control questions. |
| Not Listed | No listing found | No reviewed injectable 503A listing was identified in the reviewed materials. | Not listed is not an approval, safety clearance, or recommendation. |
| Not Reviewed | Not reviewed | No reviewed injectable 503A status has been added yet. | Neutral keeps unfinished review separate from approval or safety-risk flags. |
